To reveal the potential of 3rd generation ADC made with PSARlink technology platform, the therapeutic area on which Mablink focuses is cancer.

Mablink develops its own drug candidates with PSARlink technology:

MBK-101

Research

Preclinical

Reg. Tox. studies

Phase I

Phase II

Acute myeloid leukemia
Preclinical
Research Preclinical Reg. Tox. studies Phase I Phase II

MBK-102

Research

Preclinical

Reg. Tox. studies

Phase I

Phase II

Non-Hodgkin's lymphoma
Preclinical
Research Preclinical Reg. Tox. studies Phase I Phase II